• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    5/28/24 8:07:33 AM ET
    $AGIO
    $AKAN
    $CALT
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $AGIO alert in real time by email

    Gainers

    • Sharps Technology (NASDAQ:STSS) shares rose 193.0% to $0.63 during Tuesday's pre-market session. The market value of their outstanding shares is at $9.8 million.
    • Insmed (NASDAQ:INSM) shares moved upwards by 141.54% to $53.14. The company's market cap stands at $7.8 billion.
    • Calliditas Therapeutics (NASDAQ:CALT) shares moved upwards by 71.09% to $38.36. The market value of their outstanding shares is at $1.0 billion. As per the press release, Q1 earnings came out 3 days ago.
    • Predictive Oncology (NASDAQ:POAI) shares moved upwards by 62.45% to $2.55. The company's market cap stands at $10.4 million.
    • Corcept Therapeutics (NASDAQ:CORT) shares rose 22.42% to $33.69. The company's market cap stands at $3.5 billion.
    • Agios Pharmaceuticals (NASDAQ:AGIO) shares increased by 21.58% to $38.3. The market value of their outstanding shares is at $2.1 billion.

    Losers

    • Innovative Eyewear (NASDAQ:LUCY) shares decreased by 31.9% to $0.67 during Tuesday's pre-market session. The market value of their outstanding shares is at $11.7 million.
    • OneMedNet (NASDAQ:ONMD) stock decreased by 18.7% to $1.87. The company's market cap stands at $44.5 million.
    • Onconetix (NASDAQ:ONCO) shares fell 14.24% to $0.16. The market value of their outstanding shares is at $3.4 million.
    • eFFECTOR Therapeutics (NASDAQ:EFTR) shares decreased by 13.49% to $1.54. The market value of their outstanding shares is at $7.2 million.
    • TransCode Therapeutics (NASDAQ:RNAZ) stock fell 11.74% to $1.58. The company's market cap stands at $10.4 million.
    • Akanda (NASDAQ:AKAN) stock fell 11.2% to $3.65. The market value of their outstanding shares is at $3.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AGIO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGIO
    $AKAN
    $CALT
    $CORT

    CompanyDatePrice TargetRatingAnalyst
    Insmed Incorporated
    $INSM
    1/28/2026$231.00Overweight
    Barclays
    Insmed Incorporated
    $INSM
    1/23/2026$212.00Buy
    Roth Capital
    Corcept Therapeutics Incorporated
    $CORT
    12/31/2025$30.00Peer Perform → Underperform
    Wolfe Research
    Insmed Incorporated
    $INSM
    12/19/2025$202.00Buy
    Truist
    Corcept Therapeutics Incorporated
    $CORT
    12/16/2025Neutral
    UBS
    Insmed Incorporated
    $INSM
    12/4/2025$263.00Buy
    Rothschild & Co Redburn
    Agios Pharmaceuticals Inc.
    $AGIO
    11/24/2025Buy
    Truist
    Agios Pharmaceuticals Inc.
    $AGIO
    11/20/2025$34.00Market Perform → Outperform
    Leerink Partners
    More analyst ratings

    $AGIO
    $AKAN
    $CALT
    $CORT
    SEC Filings

    View All

    SEC Form 144 filed by Insmed Incorporated

    144 - INSMED Inc (0001104506) (Subject)

    3/5/26 4:59:55 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by TransCode Therapeutics Inc.

    DEFA14A - Transcode Therapeutics, Inc. (0001829635) (Filer)

    3/3/26 4:06:34 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Therapeutics Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)

    3/3/26 4:05:39 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIO
    $AKAN
    $CALT
    $CORT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Gross Harrison R. bought $1,980 worth of shares (1,500 units at $1.32), increasing direct ownership by 12% to 13,733 units (SEC Form 4)

    4 - Innovative Eyewear Inc (0001808377) (Issuer)

    1/22/26 11:29:05 AM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Large owner Hrt Financial Lp bought $40,650 worth of Class A Shares (29,036 units at $1.40) and sold $10,150 worth of Class A Shares (7,868 units at $1.29) (SEC Form 4)

    4 - AKANDA CORP. (0001888014) (Issuer)

    1/20/26 2:07:19 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Financial Officer Gayle Oswald bought $1,669 worth of shares (1,000 units at $1.67), increasing direct ownership by 54% to 2,865 units (SEC Form 4)

    4 - Innovative Eyewear Inc (0001808377) (Issuer)

    1/15/26 5:00:07 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    $AGIO
    $AKAN
    $CALT
    $CORT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Insmed with a new price target

    Barclays initiated coverage of Insmed with a rating of Overweight and set a new price target of $231.00

    1/28/26 7:17:09 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital initiated coverage on Insmed with a new price target

    Roth Capital initiated coverage of Insmed with a rating of Buy and set a new price target of $212.00

    1/23/26 8:19:26 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corcept Therapeutics downgraded by Wolfe Research with a new price target

    Wolfe Research downgraded Corcept Therapeutics from Peer Perform to Underperform and set a new price target of $30.00

    12/31/25 9:53:16 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIO
    $AKAN
    $CALT
    $CORT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chair and CEO Lewis William exercised 10,699 shares at a strike of $24.94 and sold $1,562,328 worth of shares (10,699 units at $146.03) (SEC Form 4)

    4 - INSMED Inc (0001104506) (Issuer)

    3/5/26 4:16:51 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sharoky Melvin Md gifted 100 shares, decreasing direct ownership by 0.04% to 242,776 units (SEC Form 4)

    4 - INSMED Inc (0001104506) (Issuer)

    3/5/26 4:15:10 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Principal Accounting Officer Washburn Theodore James Jr. sold $152,255 worth of shares (5,272 units at $28.88), decreasing direct ownership by 86% to 868 units (SEC Form 4)

    4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)

    3/5/26 4:08:15 PM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIO
    $AKAN
    $CALT
    $CORT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ARIKAYCE KIT issued to INSMED INC

    Submission status for INSMED INC's drug ARIKAYCE KIT (SUPPL-13) with active ingredient AMIKACIN SULFATE has changed to 'Approval' on 06/01/2023. Application Category: NDA, Application Number: 207356, Application Classification: Labeling

    6/2/23 4:38:39 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ARIKAYCE KIT issued to INSMED INC

    Submission status for INSMED INC's drug ARIKAYCE KIT (SUPPL-12) with active ingredient AMIKACIN SULFATE has changed to 'Approval' on 02/10/2023. Application Category: NDA, Application Number: 207356, Application Classification: Labeling

    2/13/23 4:39:32 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for PYRUKYND issued to AGIOS PHARMACEUTICALS INC

    Submission status for AGIOS PHARMACEUTICALS INC's drug PYRUKYND (ORIG-1) with active ingredient MITAPIVAT has changed to 'Approval' on 02/17/2022. Application Category: NDA, Application Number: 216196, Application Classification: Type 1 - New Molecular Entity

    2/17/22 2:39:08 PM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIO
    $AKAN
    $CALT
    $CORT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BRIDGEWATER, N.J., March 5, 2026 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 85 new employees. The awards were granted under the Insmed Incorporated 2025 Inducement Plan, which is intended to meet the requirements of a plan providing for inducement grants under Nasdaq Listing Rule 5635(c)(4). The awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.In connection with the commence

    3/5/26 7:00:00 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients

    TransCode adds a unique adenovirus technology platform to its early-stage pipeline that has the potential to address a difficult to treat disease such as muscle-invasive bladder cancer.BOSTON, March 3, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced that it has entered into an exclusive, worldwide, fully paid-up royalty-free license agreement with Unleash Immuno Oncolytics, Inc. ("Unleash"). TransCode obtained the rights to develop three Unleash drug candidates, UIO-524, UIO-525 and UIO-526, which includes a license of all in-licensed rights held by

    3/3/26 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates

    PYRUKYND is the only medicine approved in the UAE for adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia NewBridge Pharmaceuticals, a regional specialty company, will continue to manage commercialization of PYRUKYND in the Gulf region CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the Emirates Drug Establishment (EDE) of the United Arab Emirates (UAE) has approved PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, for the treatment of adult patients

    3/2/26 7:00:00 AM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIO
    $AKAN
    $CALT
    $CORT
    Leadership Updates

    Live Leadership Updates

    View All

    TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

    BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee.  Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development, diagnostics, specialty pharmaceuticals, and capital formation.

    12/22/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer

    Accomplished drug development leader to advance TransCode's mission of defeating cancer through RNA innovation and translational excellence BOSTON, Nov. 17, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), an immuno-oncology and targeted cancer therapy company with a focus on treating advanced malignancy, announced today the appointment of Dr. Michel Janicot, Ph.D., as consultant Senior Development Officer. Dr. Janicot brings more than 35 years of experience in pharmaceutical research, preclinical, and early clinical drug development across oncology and other therapeutic areas. He will serve initially on a part-time basis. 

    11/17/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Predictive Oncology Announces Additions to Board and Leadership Team to Support Digital Asset Treasury Strategy

    Appoints Shawn Matthews, CEO of DNA Holdings Venture, Inc., and Former CEO of Cantor Fitzgerald, to its Board of Directors Names Thomas McLaughlin and Sara Turken, JD, as Chief Investment Officer and General Counsel, respectively PITTSBURGH, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery and the first Strategic Compute Reserve leveraging the Aethir ecosystem to democratize access to AI infrastructure, today announced additions to its leadership team and Board of Directors in support of the Company's new digital asset treasury strategy focused on the Aethir (ATH) token. The Company announced today that Shawn Matthews, CEO of

    10/14/25 8:00:00 AM ET
    $POAI
    Industrial Specialties
    Health Care

    $AGIO
    $AKAN
    $CALT
    $CORT
    Financials

    Live finance-specific insights

    View All

    Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update

    2025 revenue of $761.4 million Full year 2026 revenue guidance of $900 – $1,000 million 2025 net income of $99.7 million Cash and investments of $532.4 million at December 31, 2025 Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter and year ended December 31, 2025. Financial Results "In 2025, our Cushing's syndrome business experienced a surge in demand due to growing recognition among physicians of hypercortisolism's true pr

    2/24/26 4:05:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update

    —Company Expects Full-Year 2026 BRINSUPRI® (brensocatib) Revenues to Be at Least $1 Billion; Reiterates Full-Year 2026 ARIKAYCE® (amikacin liposome inhalation suspension) Revenue Guidance of $450 Million to $470 Million——Total Company Revenues of $606.4 Million for Full-Year 2025——BRINSUPRI Total Revenues of $144.6 Million for Fourth-Quarter and $172.7 Million for Full-Year 2025——ARIKAYCE Total Revenues of $119.2 Million for Fourth-Quarter and $433.8 Million for Full-Year 2025, Representing 19% Annual Growth and Exceeding the Upper End of Full-Year 2025 Guidance——Topline Data Readouts from Phase 3 ENCORE and Phase 2b CEDAR Studies Remain on Track——FDA grants Orphan Drug Designation to Trepro

    2/19/26 7:00:00 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results, Provide Corporate Update and Host Conference Call

    Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report fourth quarter and full-year 2025 financial results and provide a corporate update on February 24, 2026. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors / Events tab of Corcept.com.

    2/17/26 4:05:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIO
    $AKAN
    $CALT
    $CORT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Agios Pharmaceuticals Inc.

    SC 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)

    11/14/24 3:44:53 PM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Insmed Incorporated

    SC 13G/A - INSMED Inc (0001104506) (Subject)

    11/14/24 1:22:37 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Onconetix Inc.

    SC 13G - Onconetix, Inc. (0001782107) (Subject)

    11/14/24 11:19:35 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care